Biodesix, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDBiodesix, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 97), indicating clear outperformance against the broad market. Earnings growth of 49% provides fundamental context to the price action. However, price is extended 28% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $18.59 | +9.43% | ABOVE |
| 50 SMA | $15.91 | +27.84% | ABOVE |
| 100 SMA | $15.20 | +33.84% | ABOVE |
| 150 SMA | $12.91 | +57.50% | ABOVE |
| 200 SMA | $11.52 | +76.53% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is BDSX in an uptrend right now?
BDSX has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, BDSX is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is BDSX overbought or oversold?
BDSX's RSI (14) is 63. The stock is in neutral territory, neither overbought nor oversold.
Is BDSX outperforming the market?
BDSX has a Relative Strength (RS) Rating of 97 out of 99. Yes, BDSX is a market leader, outperforming 97% of all stocks over the past 12 months.
Where is BDSX in its 52-week range?
BDSX is trading at $20.34, which is 82% of its 52-week high ($24.92) and 77% above its 52-week low ($5.26).
How volatile is BDSX?
BDSX has a Beta of 0.70 and 52-week volatility of 114%. It's less volatile than the S&P 500 - generally more stable.